Highlights Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
8.95 ^USD	-3.76%		-13.86%	+45.77%

May. 15	Solid Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 01	Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Solid Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label	Apr. 01	MT
Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	Apr. 01	CI
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Solid Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Solid Biosciences Inc. Announces Licensing Agreement with Armatus Bio for the Use of Aav-Slb101, A Proprietary, Muscle-Targeted Capsid, in the Development of an Rnai Therapy to Treat Fshd	Mar. 07	CI
Solid Biosciences Gets FDA Orphan Drug Designation for Duchenne Drug Candidate	Jan. 16	MT
Solid Biosciences Gets Orphan Drug Designation for SGT-003	Jan. 16	DJ
Solid Biosciences Says FDA Grants Fast Track Designation to Duchenne Muscular Dystrophy Gene Therapy; Shares Rise	Dec. 07	MT
Inflation, Retail Data Eyed as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Wednesday	Nov. 15	MT
Solid Biosciences New Drug Application for Duchenne Muscular Dystrophy Gets FDA Clearance; Shares Soar Premarket	Nov. 15	MT
Solid Biosciences New Drug Application for Duchenne Muscular Dystrophy Gets FDA Clearance; Shares Surge After Hours	Nov. 14	MT
Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate Sgt-003	Nov. 14	CI
Solid Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Solid Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Solid Biosciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
SOLID BIOSCIENCES INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-23	AQ
Solid Biosciences, Phlox Therapeutics to Collaborate on Heart Muscle Disease Treatments	23-01-11	MT
Solid Biosciences Inc. and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases	23-01-11	CI
Solid Biosciences Inc. completed the acquisition of AavantiBio, Inc. from a group of shareholders for $11.6 million.	22-12-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Solid Biosciences Inc.

Equities

SLDB

US83422E2046

Highlights

Filters